What is type 2 airway inflammation and why does it matter for asthma?

Type 2 airway inflammation refers to eosinophilic inflammation — an immune pattern driven by eosinophil white blood cells and cytokines such as IL-4, IL-5, and IL-13. It is the dominant inflammatory type in most adults with asthma and is associated with a strong response to inhaled corticosteroids. It can be measured indirectly through a blood eosinophil count and fractional exhaled nitric oxide (FeNO) — both available through the MBS. Knowing whether type 2 inflammation is present helps GPs and respiratory physicians decide whether to escalate to a triple inhaler, adjust steroid dose, or consider a biologic therapy.

What is a triple inhaler and who might need one for asthma?

A triple inhaler for asthma combines an inhaled corticosteroid (ICS), a long-acting beta-2 agonist (LABA), and a long-acting muscarinic antagonist (LAMA) in a single device. The new eTG option — fluticasone furoate plus umeclidinium plus vilanterol — is intended for adults and adolescents whose asthma is not controlled on optimised dual ICS/LABA therapy. Most people with mild to moderate asthma will not reach this step. This is a step 4 or 5 escalation option, and the decision to use it belongs with your GP or a respiratory specialist who can assess your full clinical picture.

eTG June 2026 respiratory update: triple inhalers added to asthma algorithm

What just happened

Therapeutic Guidelines released its June 2026 update to the Respiratory module — one of the most widely used clinical references in Australian general practice — marking the first major revision under its new living-guidelines format, which is designed to update in response to emerging evidence rather than in fixed annual editions.

Two changes are clinically significant for anyone managing asthma or COPD in general practice.

The first is the addition of a triple combination inhaler — fluticasone furoate plus umeclidinium plus vilanterol, an inhaled corticosteroid (ICS) combined with a long-acting beta-2 agonist (LABA) and a long-acting muscarinic antagonist (LAMA) — as a formal step in the asthma management algorithm for adults and adolescents whose disease remains uncontrolled on optimised dual ICS/LABA therapy. This formally adds a LAMA to the asthma escalation pathway, a class of bronchodilator that has long been standard in COPD management but whose role in asthma has been gradually clarified over recent years.

The second is the explicit incorporation of type 2 airway inflammation assessment into the treatment selection framework — a structural update that changes how GPs and respiratory physicians think about which escalation step to reach for, and when.

About 2.7 million Australians live with asthma — roughly 1 in 9 people. A significant proportion of adults with asthma are considered poorly controlled despite being on treatment. For anyone who has cycled through inhaler adjustments without reaching adequate symptom control, this update adds a more granular framework for understanding what to try next.

The both-and

The triple inhaler addition is a meaningful expansion of what the Australian guideline endorses for difficult asthma. The type 2 inflammation update is less visible but arguably more important for getting treatment right.

Triple inhalers for asthma — what actually changes

The standard escalation pathway in Australian general practice has been: reliever therapy → maintenance ICS → ICS/LABA combination → biologic therapy or specialist referral. The June 2026 eTG update formally inserts a step between optimised ICS/LABA and biologic or specialist pathways: a triple ICS/LABA/LAMA combination, specifically fluticasone furoate plus umeclidinium plus vilanterol.

LAMA bronchodilators work through muscarinic receptor antagonism — a mechanism distinct from the beta-2 agonist pathway used by SABAs and LABAs. In COPD, LAMA therapy has been standard for years (tiotropium is the most familiar Australian example). In asthma, the evidence for adding a LAMA to ICS/LABA has been building incrementally, and the eTG June 2026 revision incorporates that evidence into the formal stepwise framework. The National Asthma Council of Australia’s Australian Asthma Handbook contextualises how this fits within the broader asthma management approach.

This is not a first-line or even a second-line change. The triple combination option applies specifically to adults and adolescents — not children — on already-optimised dual ICS/LABA therapy who continue to have uncontrolled asthma. Most people with mild to moderate disease will not be at this step.

Additional asthma inhaler options added to the eTG update include mometasone plus indacaterol (Atectura Breezhaler) and mometasone plus indacaterol plus glycopyrronium (Enerzair Breezhaler) — both ICS/LABA and ICS/LABA/LAMA combinations in the Breezhaler delivery system — expanding the available device and formulation options for asthma management.

Type 2 airway inflammation — the structurally important change

The more significant shift may be the formalisation of type 2 airway inflammation testing in the treatment selection algorithm. Type 2 inflammation — eosinophilic airway inflammation characterised by elevated eosinophils and driven by immune pathways involving IL-4, IL-5, and IL-13 — is the dominant pattern in most adults with asthma and is the inflammation type that responds to inhaled corticosteroids and biologic therapies targeting those pathways.

Its clinical measurement is practical and MBS-accessible. A blood eosinophil count is a standard full blood count component. Fractional exhaled nitric oxide (FeNO) testing is more specialised but available through respiratory clinics and increasingly through general practice. Together, these give a picture of whether type 2 inflammation is driving poorly controlled asthma — which in turn informs whether escalating the ICS dose, adding a LAMA, or moving toward a biologic (such as dupilumab, mepolizumab, or benralizumab) is the more appropriate next step.

The significance of including this explicitly in the eTG framework is that it shifts the treatment decision from a purely symptom-severity-based stepwise approach to a more phenotype-informed one. That is a more accurate model of the disease and is consistent with how respiratory specialists have been thinking about severe asthma for several years. Its inclusion in eTG brings that clinical model into the reach of general practice.

For COPD

For COPD, the June 2026 eTG update adds two triple combination options for patients who continue to have symptoms and exacerbations despite dual bronchodilator and ICS therapy: beclometasone plus glycopyrronium plus formoterol (available as Trimbow) and budesonide plus glycopyrronium plus formoterol (available as Breztri Aerosphere). Both are PBS-listed for eligible patients. These are not new medications — they have been TGA-registered for some time — but their formal incorporation into the eTG stepped management framework makes them an endorsed, guideline-supported option rather than an off-algorithm choice.

2 cents

If asthma is in your picture — particularly if you or someone close to you has been on dual ICS/LABA therapy and still experiencing frequent symptoms, night waking, or exercise limitation — the June 2026 eTG update provides a useful framework for a more focused conversation with your GP or a respiratory physician.

Two questions are worth raising if poorly controlled asthma has been the ongoing story:

First: have blood eosinophils or a FeNO test been done recently? These are straightforward tests that can clarify whether type 2 inflammation is driving the disease and help guide the choice of next step. Raising this with your GP and asking whether the result would change the management plan is a reasonable question.

Second: if dual ICS/LABA has been optimised — correct device technique confirmed, adherence checked, triggers addressed — and symptoms remain uncontrolled, is a triple combination approach (now formally in the eTG algorithm) or a referral to a respiratory physician for biologic assessment the more appropriate next step?

Bringing this framing to a general practice consultation, rather than cycling through the same inhaler adjustments indefinitely, is a reasonable use of the new eTG update.

This is general health information and does not constitute individual clinical advice.

Verdict

Verdict: yes — worth knowing about.

The June 2026 eTG respiratory update adds substantive clinical options to the asthma management algorithm and formalises type 2 inflammation testing as an explicit decision point for treatment escalation. For anyone with poorly controlled asthma on dual ICS/LABA therapy, this update provides a clearer framework for what to discuss with a GP before accepting that the current regimen is the ceiling of what is available.